112 related articles for article (PubMed ID: 27509245)
1. Precursor Forms of Vitamin D Reduce HIV-1 Infection In Vitro.
Aguilar-Jimenez W; Villegas-Ospina S; Gonzalez S; Zapata W; Saulle I; Garziano M; Biasin M; Clerici M; Rugeles MT
J Acquir Immune Defic Syndr; 2016 Dec; 73(5):497-506. PubMed ID: 27509245
[TBL] [Abstract][Full Text] [Related]
2. HLA-DR+ CD38+ CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo.
Meditz AL; Haas MK; Folkvord JM; Melander K; Young R; McCarter M; Mawhinney S; Campbell TB; Lie Y; Coakley E; Levy DN; Connick E
J Virol; 2011 Oct; 85(19):10189-200. PubMed ID: 21813616
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D modulates the expression of HLA-DR and CD38 after in vitro activation of T-cells.
Villegas-Ospina S; Aguilar-Jimenez W; Gonzalez SM; Rugeles MT
Horm Mol Biol Clin Investig; 2017 Mar; 29(3):93-103. PubMed ID: 28222027
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 21 (IL-21)/microRNA-29 (miR-29) axis is associated with natural resistance to HIV-1 infection.
Ortega PAS; Saulle I; Mercurio V; Ibba SV; Lori EM; Fenizia C; Masetti M; Trabattoni D; Caputo SL; Vichi F; Mazzotta F; Clerici M; Biasin M
AIDS; 2018 Nov; 32(17):2453-2461. PubMed ID: 30005016
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D treatment of peripheral blood mononuclear cells modulated immune activation and reduced susceptibility to HIV-1 infection of CD4+ T lymphocytes.
Gonzalez SM; Aguilar-Jimenez W; Trujillo-Gil E; Zapata W; Su RC; Ball TB; Rugeles MT
PLoS One; 2019; 14(9):e0222878. PubMed ID: 31550271
[TBL] [Abstract][Full Text] [Related]
6. CD1d-restricted natural killer T cells are potent targets for human immunodeficiency virus infection.
Fleuridor R; Wilson B; Hou R; Landay A; Kessler H; Al-Harthi L
Immunology; 2003 Jan; 108(1):3-9. PubMed ID: 12519296
[TBL] [Abstract][Full Text] [Related]
7. Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.
Tuluc F; Spitsin S; Tustin NB; Murray JB; Tustin R; Schankel LA; Wiznia A; Nachman S; Douglas SD
AIDS Res Hum Retroviruses; 2017 Feb; 33(2):133-142. PubMed ID: 27615375
[TBL] [Abstract][Full Text] [Related]
8. Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection.
Prince HE; Jensen ER
J Acquir Immune Defic Syndr (1988); 1991; 4(12):1227-32. PubMed ID: 1719188
[TBL] [Abstract][Full Text] [Related]
9. Selective increase of activation antigens HLA-DR and CD38 on CD4+ CD45RO+ T lymphocytes during HIV-1 infection.
Kestens L; Vanham G; Vereecken C; Vandenbruaene M; Vercauteren G; Colebunders RL; Gigase PL
Clin Exp Immunol; 1994 Mar; 95(3):436-41. PubMed ID: 7907956
[TBL] [Abstract][Full Text] [Related]
10. During HIV infection, CD4+ CD38+ T-cells are the predominant circulating CD4+ subset whose HLA-DR positivity increases with disease progression and whose V beta repertoire is similar to that of CD4+ CD38- T-cells.
Ramzaoui S; Jouen-Beades F; Gilbert D; Borsa-Lebas F; Michel Y; Humbert G; Tron F
Clin Immunol Immunopathol; 1995 Oct; 77(1):33-41. PubMed ID: 7554481
[TBL] [Abstract][Full Text] [Related]
11. In vitro effects of the CCR5 inhibitor maraviroc on human T cell function.
Arberas H; Guardo AC; Bargalló ME; Maleno MJ; Calvo M; Blanco JL; García F; Gatell JM; Plana M
J Antimicrob Chemother; 2013 Mar; 68(3):577-86. PubMed ID: 23152485
[TBL] [Abstract][Full Text] [Related]
12. High Expression of Antiviral and Vitamin D Pathway Genes Are a Natural Characteristic of a Small Cohort of HIV-1-Exposed Seronegative Individuals.
Aguilar-Jimenez W; Saulle I; Trabattoni D; Vichi F; Lo Caputo S; Mazzotta F; Rugeles MT; Clerici M; Biasin M
Front Immunol; 2017; 8():136. PubMed ID: 28243241
[TBL] [Abstract][Full Text] [Related]
13. [The correlation between HLA-DR or CD38 expression in CD8(+)T cells and CD4(+)T cells count in treatment-naive HIV/AIDS patients].
Xie J; Qiu Z; Han Y; Li Y; Song X; Li T
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):36-9. PubMed ID: 26796651
[TBL] [Abstract][Full Text] [Related]
14. Cholecalciferol modulates the phenotype of differentiated monocyte-derived dendritic cells without altering HIV-1 transfer to CD4+ T cells.
Gonzalez SM; Aguilar-Jimenez W; Alvarez N; Rugeles MT
Horm Mol Biol Clin Investig; 2019 Sep; 40(1):. PubMed ID: 31539353
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of HIV-1 p24 antigenemia and level of CD8+CD38+ T cells as surrogate markers of HIV-1 RNA viral load in HIV-1-infected patients in Dakar, Senegal.
Ondoa P; Dieye TN; Vereecken C; Camara M; Diallo AA; Fransen K; Litzroth A; Mboup S; Kestens L
J Acquir Immune Defic Syndr; 2006 Apr; 41(4):416-24. PubMed ID: 16652048
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of CD80 and CD86 in in vitro-infected CD3+ cells producing cytoplasmic HIV type 1 p24.
Jason J; Inge KL
AIDS Res Hum Retroviruses; 1999 Jan; 15(2):173-81. PubMed ID: 10029249
[TBL] [Abstract][Full Text] [Related]
17. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V
J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625
[TBL] [Abstract][Full Text] [Related]
18. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
[TBL] [Abstract][Full Text] [Related]
19. The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline.
Kramer VG; Hassounah S; Colby-Germinario SP; Oliveira M; Lefebvre E; Mesplède T; Wainberg MA
J Antimicrob Chemother; 2015 Mar; 70(3):750-6. PubMed ID: 25433008
[TBL] [Abstract][Full Text] [Related]
20. R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors.
Gondois-Rey F; Biancotto A; Fernandez MA; Bettendroffer L; Blazkova J; Trejbalova K; Pion M; Hirsch I
J Virol; 2006 Jan; 80(2):854-65. PubMed ID: 16378987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
